RPS invites responses to pharmacogenomics prescribing consultation The Royal Pharmaceutical Society said that its draft pharmacogenomic resource offers reflections on how competencies taken from its ‘Competency framework for all prescribers’ apply to pharmacogenomics.…
How can the NHS make the most of the paediatric pharmacogenomics opportunity? Attendees at a roundtable hosted by The Pharmaceutical Journal discussed challenges around implementing pharmacogenomic prescribing in the NHS and particular considerations for paediatric patients.… Supported content
MHRA sets out plans to speed up access to rare disease therapies The Medicines and Healthcare products Regulatory Agency said “the rulebook for rare disease therapies will be overhauled" to make it quicker and easier to get therapies tested and approved.…
MHRA publishes ‘world first’ decentralised manufacturing guidance The guidance will inform the manufacture of medicines with a short shelf-life or highly personalised medicines at sites within or in close proximity to hospitals.…
NHS pharmacogenomics trial expands to 20 sites across England The PROGRESS trial is planned to finish in early 2026, with an impact assessment produced in the fourth quarter of 2025/2026.…
Genetic testing could prevent three-quarters of avoidable side effects of some medicines, study suggests Researchers found that patients experiencing adverse drug reactions to treatments for psychiatric disorders and cardiovascular problems could benefit the most from personalised prescribing with pharmacogenomics.…
Rapid on-site genetic sequencing could help curb antimicrobial-resistant outbreaks, says MHRA Researchers found that rapid on-site genetic sequencing detects bacterial infections within two days, which is “significantly faster“ than traditional methods.…
Nine in ten people would accept a pharmacogenomics test, reveals survey The majority of respondents to a survey said they would be motivated to take a pharmacogenomics test to enhance drug effectiveness and reduce the risk of adverse drug reactions.…
Pharmacogenomics trial expands across England Programme co-ordinators are aiming to recruit a further 1,450 people to the second phase of the PROGRESS trial, which is the first in the UK to introduce genetic testing before prescribing in primary care.…
NICE approves gene-editing sickle cell therapy for NHS in England Exagamglogene autotemcel, also known as exa-cel, is now recommended for NHS use, reversing previous draft guidance.…
